Differential regulation of arylamine and arylalkylamine N-acetyltransferases in human retinoblastoma (Y-79) cells.
For the first time, arylamine and arylalkylamine N-acetyltransferase (NAT) activities are shown to be differentially regulated. In a human retinoblastoma (Y-79) cell line, arylalkylamine NAT activity, but not arylamine NAT activity increased (3-5-fold) rapidly (1-3 h) in response to treatment with dibutyryl cAMP. In contrast, treatment with butyrate showed a delayed (3-5 days) increase (3-5-fold) in arylamine NAT activity but not in arylalkylamine NAT activity. The differential response to these agents in Y-79 cells provides a model system for future studies on the regulatory relationship between the two enzyme activities.
Department of Biology, Georgetown University, Washington, DC 20057.
S J
SJ
Gaudet
B J
BJ
Hayden
G J
GJ
Chader
M A
MA
Namboodiri
D015124:8-Bromo Cyclic Adenosine Monophosphate / Q000494:pharmacology; D001191:Arylamine N-Acetyltransferase / Q000378:metabolism*; D003994:Bucladesine / Q000494:pharmacology; D002087:Butyrates / Q000494:pharmacology; D020148:Butyric Acid; D005134:Eye Neoplasms / Q000201:enzymology* / Q000473:pathology; D006801:Humans; D012175:Retinoblastoma / Q000201:enzymology* / Q000473:pathology; D014407:Tumor Cells, Cultured
D002087:Butyrates; D020148:Butyric Acid; D015124:8-Bromo Cyclic Adenosine Monophosphate; D003994:Bucladesine; D001191:Arylamine N-Acetyltransferase